AR039783A1 - Metodos mejorados de purificacion viral - Google Patents
Metodos mejorados de purificacion viralInfo
- Publication number
- AR039783A1 AR039783A1 ARP030101504A ARP030101504A AR039783A1 AR 039783 A1 AR039783 A1 AR 039783A1 AR P030101504 A ARP030101504 A AR P030101504A AR P030101504 A ARP030101504 A AR P030101504A AR 039783 A1 AR039783 A1 AR 039783A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- viruses
- cell culture
- improved methods
- detergent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 9
- 238000004113 cell culture Methods 0.000 abstract 3
- 239000003599 detergent Substances 0.000 abstract 2
- 241000702263 Reovirus sp. Species 0.000 abstract 1
- 239000013592 cell lysate Substances 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000004440 column chromatography Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se refiere a un método mejorado de purificación de virus, en particular reovirus. Se pueden extraer virus infecciosos de un cultivo celular con un detergente para producir títulos virales más altos y el virus puede ser purificado luego mediante pasos simples tal como filtración y cromatografía en columna. También se proveen virus y composiciones que comprenden virus preparadas de acuerdo con la presente. Reivindicación 1: Un método para producir virus a partir de un cultivo de células, caracterizado porque comprende los pasos de: a) proveer un cultivo de células que ha sido infectado con el virus; b) extraer el virus de las células por adición de un detergente al cultivo e incubarlo por un período de tiempo para obtener un lisado celular; c) eliminar los desechos celulares; y d) recolectar el virus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37727302P | 2002-04-30 | 2002-04-30 | |
US44317603P | 2003-01-29 | 2003-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039783A1 true AR039783A1 (es) | 2005-03-02 |
Family
ID=29406789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030101504A AR039783A1 (es) | 2002-04-30 | 2003-04-29 | Metodos mejorados de purificacion viral |
Country Status (17)
Country | Link |
---|---|
US (3) | US7223585B2 (es) |
EP (1) | EP1501921B2 (es) |
JP (1) | JP2005523722A (es) |
AR (1) | AR039783A1 (es) |
AT (1) | ATE427990T1 (es) |
AU (1) | AU2003229159B2 (es) |
BR (1) | BR0309659A (es) |
CA (1) | CA2482512C (es) |
DE (1) | DE60327069D1 (es) |
DK (1) | DK1501921T4 (es) |
ES (1) | ES2323454T5 (es) |
HK (1) | HK1070670A1 (es) |
IL (1) | IL164551A (es) |
MX (1) | MXPA04010603A (es) |
NZ (1) | NZ535944A (es) |
TW (1) | TWI317378B (es) |
WO (1) | WO2003093463A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003229159B2 (en) | 2002-04-30 | 2008-02-21 | Oncolytics Biotech Inc. | Improved viral purification methods |
AU2004249802B2 (en) | 2003-06-20 | 2007-06-28 | Microbix Biosystems Inc. | Improvements in virus production |
US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
US8373381B2 (en) | 2005-04-22 | 2013-02-12 | GM Global Technology Operations LLC | DC/DC-less coupling of matched batteries to fuel cells |
US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
WO2007099401A2 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
AU2007240797B2 (en) | 2006-04-20 | 2013-05-23 | Wyeth Llc | Purification processes for isolating purified vesicular stomatitis virus from cell culture |
US20080131955A1 (en) * | 2006-11-30 | 2008-06-05 | Canon U.S. Life Sciences, Inc. | Method of Separating Target DNA from Mixed DNA |
US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
CN102215865B (zh) * | 2008-09-24 | 2013-10-30 | 米迪缪尼有限公司 | 病毒纯化方法 |
JP2013523175A (ja) | 2010-04-14 | 2013-06-17 | イーエムディー・ミリポア・コーポレーション | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
AU2011336410B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
WO2012075379A2 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Liquid viral formulations |
EA201391605A1 (ru) * | 2011-04-29 | 2014-02-28 | Онколитикс Байотек Инк. | Способы очистки вирусов с использованием гельпроникающей хроматографии |
ES2681434T3 (es) * | 2013-03-15 | 2018-09-13 | The Children's Hospital Of Philadelphia | Procedimiento de fabricación escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspensión libre de suero |
FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
US20160329387A1 (en) * | 2014-01-14 | 2016-11-10 | Koninklijke Philips N.V. | Organic light emitting diode |
WO2016130569A1 (en) * | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
RU2020109343A (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
DK3218386T3 (da) | 2014-11-14 | 2021-06-07 | Voyager Therapeutics Inc | Modulatorisk polynukleotid |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
EP3368054A4 (en) | 2015-10-28 | 2019-07-03 | Voyager Therapeutics, Inc. | REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV) |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
IL302748A (en) | 2016-05-18 | 2023-07-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
CN109831916B (zh) | 2016-05-18 | 2023-07-21 | 沃雅戈治疗公司 | 治疗亨廷顿氏舞蹈病的组合物和方法 |
EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
CN110913866A (zh) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | NETWORK EQUIPMENT TRACK GUIDE SYSTEM |
EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
EP3762500A1 (en) | 2018-03-06 | 2021-01-13 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
JP2021529513A (ja) | 2018-07-02 | 2021-11-04 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症および脊髄に関連する障害の治療 |
US20210355454A1 (en) | 2018-07-24 | 2021-11-18 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
AU2020208467A1 (en) | 2019-01-18 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing AAV particles |
TW202106879A (zh) | 2019-04-29 | 2021-02-16 | 美商航海家醫療公司 | 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法 |
WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2021041485A1 (en) | 2019-08-26 | 2021-03-04 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
EP4192514A1 (en) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
US20240141377A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4721675A (en) | 1982-02-01 | 1988-01-26 | Abbott Laboratories | Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system |
JPS6344532A (ja) | 1986-08-11 | 1988-02-25 | Biseibutsu Kagaku Kenkyusho:Kk | 豚のレオウイルス感染症ワクチン |
US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5658779A (en) * | 1992-03-20 | 1997-08-19 | Ligochem, Inc. | Method of adsorbing viruses from fluid compositions |
DZ1706A1 (fr) | 1992-08-07 | 2002-02-17 | Merck & Co Inc | Vaccin contre le virus de l'hepatite a. |
FR2696748B1 (fr) * | 1992-10-14 | 1994-12-30 | Pasteur Merieux Serums Vacc | Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV). |
US5614413A (en) | 1993-07-01 | 1997-03-25 | The Uab Research Foundation | Encapsidated recombinant poliovirus nucleic acid and methods of making and using same |
US6686200B1 (en) | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
HRP950097A2 (en) | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
MXPA96005662A (es) | 1994-05-16 | 2004-08-19 | Merck & Co Inc | Vacunas de papilomavirus. |
US6146873A (en) | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
AR004464A1 (es) | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
EP0847442A1 (en) * | 1995-08-30 | 1998-06-17 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
KR100503701B1 (ko) * | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
ATE477320T1 (de) | 1996-12-13 | 2010-08-15 | Schering Corp | Methoden zur virus-reinigung |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US6214333B1 (en) | 1997-07-08 | 2001-04-10 | Texas Heart Institute | Vasoprotective recombinant adenovirus vector containing a human TFPI gene |
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
AU2001275191A1 (en) | 2000-05-31 | 2001-12-11 | Chiron Corporation | Method for the purification of alphavirus replicon particles |
TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
BR0207527A (pt) | 2001-03-16 | 2004-02-25 | Oncolytics Biotech Inc | Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso |
AU2003229159B2 (en) | 2002-04-30 | 2008-02-21 | Oncolytics Biotech Inc. | Improved viral purification methods |
US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
-
2003
- 2003-04-28 AU AU2003229159A patent/AU2003229159B2/en not_active Expired
- 2003-04-28 DE DE60327069T patent/DE60327069D1/de not_active Expired - Lifetime
- 2003-04-28 EP EP03724692A patent/EP1501921B2/en not_active Expired - Lifetime
- 2003-04-28 WO PCT/CA2003/000624 patent/WO2003093463A1/en active Application Filing
- 2003-04-28 DK DK03724692.3T patent/DK1501921T4/da active
- 2003-04-28 MX MXPA04010603A patent/MXPA04010603A/es active IP Right Grant
- 2003-04-28 BR BR0309659-9A patent/BR0309659A/pt not_active IP Right Cessation
- 2003-04-28 CA CA2482512A patent/CA2482512C/en not_active Expired - Lifetime
- 2003-04-28 AT AT03724692T patent/ATE427990T1/de not_active IP Right Cessation
- 2003-04-28 NZ NZ535944A patent/NZ535944A/en unknown
- 2003-04-28 JP JP2004501599A patent/JP2005523722A/ja active Pending
- 2003-04-28 ES ES03724692T patent/ES2323454T5/es not_active Expired - Lifetime
- 2003-04-29 TW TW092109972A patent/TWI317378B/zh not_active IP Right Cessation
- 2003-04-29 US US10/424,985 patent/US7223585B2/en not_active Expired - Lifetime
- 2003-04-29 AR ARP030101504A patent/AR039783A1/es unknown
-
2004
- 2004-10-13 IL IL164551A patent/IL164551A/en active IP Right Grant
-
2005
- 2005-04-04 HK HK05102826.1A patent/HK1070670A1/xx not_active IP Right Cessation
-
2007
- 2007-04-17 US US11/736,479 patent/US8685734B2/en active Active
-
2014
- 2014-02-07 US US14/175,214 patent/US10167452B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR0309659A (pt) | 2005-02-22 |
CA2482512A1 (en) | 2003-11-13 |
US10167452B2 (en) | 2019-01-01 |
DK1501921T3 (da) | 2009-06-22 |
DE60327069D1 (de) | 2009-05-20 |
US20040005693A1 (en) | 2004-01-08 |
IL164551A (en) | 2010-05-17 |
EP1501921B1 (en) | 2009-04-08 |
US20140178969A1 (en) | 2014-06-26 |
TW200401829A (en) | 2004-02-01 |
DK1501921T4 (da) | 2012-10-08 |
US8685734B2 (en) | 2014-04-01 |
CA2482512C (en) | 2011-09-20 |
ES2323454T5 (es) | 2012-11-14 |
HK1070670A1 (en) | 2005-06-24 |
ES2323454T3 (es) | 2009-07-16 |
TWI317378B (en) | 2009-11-21 |
NZ535944A (en) | 2007-11-30 |
EP1501921A1 (en) | 2005-02-02 |
AU2003229159B2 (en) | 2008-02-21 |
US7223585B2 (en) | 2007-05-29 |
ATE427990T1 (de) | 2009-04-15 |
WO2003093463A1 (en) | 2003-11-13 |
US20070269856A1 (en) | 2007-11-22 |
MXPA04010603A (es) | 2004-12-13 |
AU2003229159A1 (en) | 2003-11-17 |
EP1501921B2 (en) | 2012-07-25 |
IL164551A0 (en) | 2005-12-18 |
JP2005523722A (ja) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039783A1 (es) | Metodos mejorados de purificacion viral | |
BRPI0516221A (pt) | método de produção de vìrus de uma cultura de células, composição, e, método de produção de reovìrus infeccioso | |
AR123811A2 (es) | Composiciones de células madre mesenquimáticas purificadas y métodos relacionados | |
EA200601231A1 (ru) | Дефинитивная энтодерма | |
DK1526172T3 (da) | Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira | |
CL2011001906A1 (es) | Compuestos derivados de ribosidos de tieno[3,4-d]pirimidin-7-ilo, y fosfatos de ribosidos; compuestos intermediarios; metodos de preparacion; metodo de tratamiento; composicion farmaceutica; y su uso para tratar una infeccion viral causada por un virus hepatitis c o un virus flaviridae. | |
AR034216A1 (es) | Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus | |
HK1080507A1 (en) | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions | |
ES2530694T3 (es) | Factor de permisividad celular para virus, y usos del mismo | |
CO2022010432A2 (es) | Método basado en tecnología leaper para el tratamiento de mucopolisacaridosis ih y composición | |
DE69740002D1 (de) | Tierzellen und verfahren für die replikation von influenza viren | |
PE20091218A1 (es) | Anticuerpo anti-glipicano 3 con cinetica en plasma mejorada | |
EA200801221A1 (ru) | Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк | |
WO2005042728A3 (en) | Immortalized avian cell lines for virus production | |
DK1428878T3 (da) | Fremgangsmåde til produktion og oprensning af erythropoietin | |
EA201270173A1 (ru) | Получение полиовируса с высокими титрами для получения вакцины | |
DK1889834T3 (da) | Ny organisk forbindelse og fremgangsmåde til at fremstille radioaktiv halogenmærket organisk forbindelse ved anvendelse af samme | |
EA201291225A1 (ru) | Улучшенные способы получения сквалена | |
WO2006038129A3 (en) | Hepatitis c virus replication system | |
AR079710A1 (es) | Proceso para el cultivo de celulas adherentes | |
CL2008003821A1 (es) | Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado | |
AR060686A1 (es) | Purificacion de trombina | |
BR9813099A (pt) | Seleção positiva-negativa na recombinação homóloga | |
BRPI0914805B8 (pt) | método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição | |
DE60143810D1 (de) | Vakzine gegen ipnv die aus hefezellen isoliert werden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |